Document ID: Z_2_11
Section: Molecular Biology & Genomics
Keywords: major histocompatibility complex, MHC, HLA, human leukocyte antigen, adaptive immunity, antigen presentation, HLA diversity, balancing selection, heterozygote advantage, MHC polymorphism, transplant rejection, autoimmune disease, HLA-B_2_11, ankylosing spondylitis, type 1 diabetes HLA, mate choice MHC, peptide binding groove, class I MHC, class II MHC, pathogen-driven selection, supratypes, killer immunoglobulin-like receptors, KIR, immune evasion
Category Tags: genetics, human-origins, medicine-healing
Cross-References: Z_2_07 — Genetics Disease Resistance · Z_3_05 — Viral Integration ERVs · L_2_02 — Population Genetics · R_2_05 — Immune System Evolution · Z_3_03 — Human Migration Genetics
Reliability Tier: Tier 1 (Nobel Prize-recognized immunology with extensive clinical genetics)
Last Updated: Mar 7, 2026 | Source Count: 11 | Weighted Score: 30 | Source Confidence: [4/5] | Confidence: High

QUICK SUMMARY

The major histocompatibility complex (MHC) — known as the human leukocyte antigen (HLA) system in humans — is the most polymorphic gene region in the human genome, encoding cell-surface glycoproteins essential for adaptive immune recognition. The HLA region spans ~4 Mb on chromosome 6p21.3 and contains >200 genes, including the classical antigen-presenting molecules: Class I (HLA-A, HLA-B, HLA-C) — expressed on nearly all nucleated cells, present intracellular peptides (viral, tumor) to CD8+ T cells; and Class II (HLA-DR, HLA-DQ, HLA-DP) — expressed on antigen-presenting cells (dendritic cells, macrophages, B cells), present extracellular/endosomal peptides to CD4+ T cells. The extreme polymorphism of HLA genes (>35,000 HLA alleles catalogued by 2024, IPD-IMGT/HLA database) is maintained by balancing selection — primarily pathogen-driven selection favoring heterozygosity (heterozygous individuals present a broader repertoire of pathogenic peptides) and frequency-dependent selection (rare alleles have advantage against pathogens that have evolved to evade common alleles). HLA diversity has profound medical significance: HLA matching is critical for organ and bone marrow transplantation (Nobel Prize to Dausset, 1980; Thomas, 1990); specific HLA alleles confer strong disease susceptibility — HLA-B_2_11 and ankylosing spondylitis (OR ~90–100), HLA-DRB104 and rheumatoid arthritis, HLA-DQ2/DQ8 and celiac disease, HLA-DRB115:01 and multiple sclerosis; virtually all autoimmune diseases show HLA associations. The HLA-B*57:01 allele is associated with both HIV viral load control ("elite controllers") and severe hypersensitivity to the antiretroviral drug abacavir — a landmark example of pharmacogenomics. Beyond classical antigen presentation, killer immunoglobulin-like receptors (KIRs) on natural killer cells interact with HLA Class I molecules in an independent co-evolutionary system influencing innate immunity and reproductive success. MHC diversity also extends to controversial evidence for MHC-disassortative mate choice in humans — preference for partners with dissimilar HLA genotypes, potentially mediated by olfactory cues.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 MHC Structure and Function

• Genomic organization: The MHC/HLA region on chromosome 6p21.3 (~4 Mb) contains three subregions — Class I (telomeric: HLA-A, -B, -C), Class III (central: complement genes C2/C4/factor B, TNF, heat shock proteins), Class II (centromeric: HLA-DR, -DQ, -DP chains)
• Class I molecules: α-chain (encoded by HLA genes) + β₂-microglobulin (chromosome 15); the peptide-binding groove (formed by α1 and α2 domains) accommodates peptides of 8–10 amino acids; expressed on virtually all nucleated cells; present intracellular peptides to CD8+ cytotoxic T lymphocytes
• Class II molecules: α-chain + β-chain (both MHC-encoded); peptide-binding groove (α1 + β1 domains) accommodates longer peptides (13–25 amino acids, open-ended groove); restricted expression on professional antigen-presenting cells (APCs); present exogenous peptides to CD4+ helper T cells
• Peptide binding specificity: Each HLA allele binds a characteristic set of peptides based on anchor residue preferences at specific pockets (B and F pockets in Class I) — the polymorphic residues that line the binding groove determine which peptides can be presented

1.2 Extreme Polymorphism

• Scale: >35,000 HLA alleles catalogued (IPD-IMGT/HLA Database, 2024); HLA-B alone has >8,000 known alleles — making it the most polymorphic coding locus in the human genome; HLA-A (~7,500), HLA-C (~7,000), HLA-DRB1 (~3,500) are also extremely diverse
• Trans-species polymorphism: Some HLA allelic lineages predate speciation — shared polymorphisms are found between humans and chimpanzees (and even Old World monkeys), meaning certain allelic lineages have been maintained by balancing selection for >30 million years (Klein 1987)
• Selection mechanisms maintaining diversity:
• Heterozygote advantage (overdominance): Individuals heterozygous at HLA loci present a broader repertoire of pathogenic peptides → enhanced immune surveillance; demonstrated experimentally in HIV (heterozygotes at HLA-A show lower viral loads; Carrington et al. 1999) and hepatitis B
• Negative frequency-dependent selection: Rare HLA alleles confer advantage because pathogens evolve to evade common alleles; as an allele becomes rare, it becomes more effective → frequency increases → equilibrium maintains many alleles
• Fluctuating selection: Different pathogens in different environments and time periods select for different HLA alleles → geographic variation in allele frequencies

1.3 HLA and Transplantation

• Discovery: Jean Dausset (Nobel Prize, 1980) identified the first HLA antigen (MAC, now HLA-A2) in 1958 through leukoagglutination studies; Baruj Benacerraf and George Snell (co-Nobel laureates) elucidated MHC function in immune responses
• Transplant matching: HLA mismatch between donor and recipient triggers alloimmune rejection — T cells recognize non-self HLA molecules (direct allorecognition) or donor peptides presented by self-HLA (indirect); matching at HLA-A, -B, -C, -DRB1, -DQB1 (10/10 match) improves outcomes in bone marrow transplantation
• Bone marrow donor registries: >40 million volunteer donors worldwide (Be The Match, DKMS, etc.); finding a 10/10 match for patients of European ancestry: ~75%; for patients of non-European or mixed ancestry: 30–50% — reflecting lower representation and higher HLA diversity in minority populations

1.4 HLA and Disease Associations

• Autoimmune diseases (strongest associations):
• Ankylosing spondylitis: HLA-B*27 — odds ratio ~90–100; ~90% of patients carry B_2_11 vs. ~8% of general European population; mechanism involves arthrogenic peptide presentation and/or HLA-B_2_11 misfolding/unfolded protein response
• Type 1 diabetes: HLA-DR3/DR4 and DQ2/DQ8 — confer ~50% of genetic risk; HLA-DQB1*06:02 is strongly protective (OR ~0.02)
• Celiac disease: HLA-DQ2 (DQA105:01/DQB102:01, ~95% of patients) and HLA-DQ8 — present deamidated gliadin peptides to gluten-reactive T cells; HLA-DQ2/DQ8 are necessary but not sufficient
• Rheumatoid arthritis: HLA-DRB1 "shared epitope" (specific amino acid sequence at positions 70–74) — OR 3–5
• Multiple sclerosis: HLA-DRB115:01 — OR ~3; epistatic interactions with HLA-A02 (protective)
• Infectious disease:
• HIV control: HLA-B57:01 and HLA-B27:05 independently associated with lower viral load and slower progression to AIDS ("elite controllers"); mechanism: effective presentation of conserved HIV Gag epitopes → strong CD8+ T-cell responses
• Abacavir hypersensitivity: HLA-B57:01 predisposes to severe hypersensitivity reaction to this antiretroviral drug — pharmacogenomic testing (HLA-B57:01 screening before prescription) is now standard of care worldwide; a paradigm for precision medicine

2. CREDIBLE CLAIMS (Tier 2 — Strong Evidence, Active Research)

2.1 KIR-HLA Co-Evolution

• Killer immunoglobulin-like receptors (KIRs): Encoded on chromosome 19q13.4; NK cell receptors that recognize HLA Class I molecules; both activating and inhibitory KIRs exist — the balance determines NK cell activation against infected or transformed cells
• Haplotype diversity: KIR haplotypes vary dramatically between populations — Group A haplotypes (more inhibitory KIRs) vs. Group B (more activating); KIR-HLA combinations influence: infectious disease outcome (KIR3DL1 + HLA-Bw4 → protective in HIV), reproductive success (uterine NK cells + KIR + HLA-C on trophoblast → placentation), and autoimmune risk
• Co-evolutionary dynamics: KIR and HLA evolve on different chromosomes but are functionally interdependent — creating complex epistatic selection; some KIR-HLA combinations are overrepresented (selected for) and others underrepresented (selected against) across human populations

2.2 MHC and Mate Choice

• "T-shirt studies" (Wedekind et al. 1995): Women shown to prefer the body odor of men with dissimilar HLA genotypes — potentially promoting HLA-heterozygous offspring with broader immune competence; effect reversed in women on oral contraceptives
• Mechanism hypothesis: MHC-influenced volatile peptide ligands detected by olfactory system; supported in mice (MHC-congenic mate choice well-documented; involvement of vomeronasal organ and main olfactory epithelium); human evidence is mixed and debated
• Reproductive outcomes: Some published findings demonstrate MHC-similar couples have higher rates of recurrent spontaneous abortion and longer time-to-conception — but results are not consistently replicated; population-level assortative mating based on HLA remains controversial

2.3 COVID-19 and HLA

• SARS-CoV-2 susceptibility and severity show HLA associations — HLA-A02:01 and HLA-B15:01 associated with mild disease in some cohorts; HLA-DRB1*15:01 associated with severity in certain populations; SARS-CoV-2 ORF8 protein implicated in downregulating MHC Class I expression (immune evasion)
• Results have been inconsistent across studies due to population heterogeneity, variable phenotype definitions, and complex confounders — robust replicated HLA associations remain limited compared to other host genetic factors (e.g., IFNAR2, OAS1)

3. SPECULATIVE CLAIMS (Tier 3 — Emerging / Theoretical)

3.1 MHC Supertypes and Vaccine Design

• Grouping HLA alleles into supertypes based on shared peptide-binding specificities (e.g., 9 Class I supertypes covering >95% of global population) — designing universal T-cell epitope vaccines that bind multiple supertypes simultaneously; approach applied to HIV, malaria, and cancer vaccine development; promising in theory but limited clinical success to date

3.2 MHC Paleogenomics

• Ancient DNA analyses of HLA diversity in archaic hominins — Neanderthal/Denisovan HLA alleles introgressed into modern humans and may have provided adaptive advantage upon entering new environments (Abi-Rached et al. 2011); HLA-A11 and HLA-B73 in modern Eurasians potentially derive from Denisovan introgression; ancient immune gene exchange as an adaptive mechanism is plausible but difficult to definitively prove

4. DUBIOUS CLAIMS (Tier 4 — Fringe / Unsubstantiated)

4.1 MHC as Sole Immunity Determinant [OVERSIMPLIFIED]

• Claims that HLA genotype alone determines immune competence or disease susceptibility are oversimplified — the immune system involves thousands of genes (innate immunity, cytokines, T-cell receptors, B-cell receptors, complement), environmental exposures, microbiome interactions, and epigenetic regulation; HLA is the single most important genetic locus for adaptive immunity but functions within a vastly complex system

IMAGES

Counter-Arguments & Criticisms

No significant counter-arguments exist in the scholarly literature for the core claims presented here. The topic of Genetics Immunity MHC Diversity represents established knowledge within molecular biology and biochemistry with no active scholarly dispute over the fundamental claims presented in this document.

BIBLIOGRAPHY

1. Klein, J. . , 19(3), 155 162 | 1987 | "Origin of Major Histocompatibility Complex Polymorphism: The Trans-Species Hypothesis" | Human Immunology | ∅ | ∅ | ∅ | ∅ | doi:10.1016/0198-8859(87)90066-8 | ∅ | ∅ | ∅
2. Carrington, M. et al. . , 283(5408), 1748 1752 | 1999 | "HLA and HIV-1: Heterozygote Advantage and B35-Cw04 Disadvantage" | Science | ∅ | ∅ | ∅ | ∅ | doi:10.1126/science.283.5408.1748 | ∅ | ∅ | ∅
3. Trowsdale, J.; Knight, J | 2013 | "Major Histocompatibility Complex Genomics and Human Disease" | Annual Review of Genomics and Human Genetics | ∅ | ∅ | C. . , 14, 301 323 | ∅ | doi:10.1146/annurev-genom-091212-153455 | ∅ | ∅ | ∅
4. Robinson, J. et al. . , 48(D1), D783 D788 | 2020 | "IPD-IMGT/HLA Database" | Nucleic Acids Research | ∅ | ∅ | ∅ | ∅ | doi:10.1093/nar/gku1161 | ∅ | ∅ | ∅
5. Parham, P.; Moffett, A. . , 13(2), 133 144 | 2013 | "Variable NK Cell Receptors and Their MHC Class I Ligands in Immunity, Reproduction and Human Evolution" | Nature Reviews Immunology | ∅ | ∅ | ∅ | ∅ | doi:10.1038/nri3370 | ∅ | ∅ | ∅
6. Mallal, S. et al. . , 358(6), 568 579 | 2008 | "HLA-B5701 Screening for Hypersensitivity to Abacavir" | New England Journal of Medicine* | ∅ | ∅ | ∅ | ∅ | doi:10.1056/NEJMoa0705931 | ∅ | ∅ | ∅
7. Wedekind, C. et al. . , 260(1359), 245 249 | 1995 | "MHC-Dependent Mate Preferences in Humans" | Proceedings of the Royal Society B | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
8. Abi-Rached, L. et al. . , 334(6052), 89 94 | 2011 | "The Shaping of Modern Human Immune Systems by Multiregional Admixture with Archaic Humans" | Science | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
9. Brown, J | 1993 | "Three-Dimensional Structure of the Human Class II Histocompatibility Antigen HLA-DR1" | Nature | ∅ | ∅ | H. et al. . , 364, 33 39 | ∅ | doi:10.1038/364033a0 | ∅ | ∅ | ∅
10. de Bakker, P | 2006 | "A High-Resolution HLA and SNP Haplotype Map for Disease Association Studies in the Extended Human MHC" | Nature Genetics | ∅ | ∅ | I | ∅ | doi:10.1038/ng1885 | ∅ | ∅ | W. et al. . , 38(10), 1166 1172
11. Kelley, Julia, et al | 2005 | "Comparative Genomics of Major Histocompatibility Complexes" | Immunogenetics | ∅ | 57.10::709–715 | ∅ | ∅ | doi:10.1007/s00251-005-0044-7 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

• Z_2_07 — Genetics Disease Resistance: Pathogen resistance alleles and balancing selection overlap
• Z_3_05 — Viral Integration ERVs: Endogenous retrovirus elements within the MHC region
• L_2_02 — Population Genetics: Balancing selection as departure from Hardy-Weinberg equilibrium
• R_2_05 — Immune System Evolution: Evolutionary origins of adaptive immunity and MHC
• Z_3_03 — Human Migration Genetics: Geographic distribution of HLA allele frequencies

Last verified: Mar 07, 2026 — All sources peer-reviewed or from established immunogenetics literature

Corrections

• 1 truncated DOI in the bibliography reassembled — Elsevier identifiers of the form 10.1016/0004-6981(72)90076-5 contain a parenthesised year, and an upstream parse treated the opening bracket as a field break: each DOI was cut short and its tail ()90076-5) left stranded in a neighbouring column. The two halves were rejoined from this same line — it was then confirmed to resolve against Crossref before being written, so no identifier was reconstructed on faith. Repaired: 10.1016/0198-8859(87)90066-8. Corpus hygiene campaign, Phase 4, 2026-07-29.